Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
Name of applicant: ALLERGY THERAPEUTICS PLC
Name of scheme: Allergy Therapeutics plc 2013 Long Term Incentive Plan
Period of return
From: 11 July 2018
To: 1 July 2020
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: 10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on 24 November 2017
Balance of unallotted securities under scheme(s) from previous return: 7,949,152
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for)
Less: Number of securities issued/allotted under scheme(s) during period: 1,117,188
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 6,831,964
Tel: +44 (0) 1903 845 820
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Other adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY).
(C) 2020 Electronic News Publishing, source ENP Newswire